메뉴 건너뛰기

On May 4, 1953, Aju Pharm started operations to help patients suffering from tuberculosis amidst the ruins of the Korean War.

ss
By the end of the Korean War, Korea experienced one of the most difficult period in its history. Due to the necessity of importing antituberculosis drugs from other countries, the high cost of these drugs left many Koreans unable to afford the treatment. To alleviate this problem, the late Kim Kwang-nam founded Aju Pharm and successfully began the first domestic production of antituberculosis medication.

66 years dedicated to improving health

On May 4, 1953, Aju Pharm started operations to help patients
suffering from tuberculosis amidst the ruins of the Korean War.

Our Story

Starting with only a single antituberculosis medicine, Aju Pharm has developed into one of the leading pharmaceutical companies providing 120 different high-quality products to various countries around the world. Presently, through our various businesses which include manufacturing of medical devices and health supplements, as well as CMO services, our goal is to provide not only treatments for patients but also to assist otherwise healthy individuals to reach their optimum health so that they made lead healthier and happier lives.
  • 1950

    1. 1953

      Aju Pharm (formerly known as Asia Pharmaceutical) founded by the late Kim Kwang-nam in Bosu-dong, Busan.

      The first domestic production of antituberculosis drug, Asiazit, is manufactured.

    2. 1956

      Headquarters moved to Yongsan-gu, Seoul.

    3. 1959

      New headquarters and factory completed in Shinrim-dong, Guro-gu, Seoul.

      Releases Compral, an antipyretic analgesic agent, manufactured through a collaborative alliance with Bayer.

  • 1960

    1. 1961

      Launch of Abomin, a medication which provides relief from vomiting of pregnancy and motion sickness, manufactured in partnership with the British company, May & Baker.

      Releases antituberculosis drug, Almiaspas, in partnership with the Japanese company, Tanabe Pharma.

    2. 1963

      Expansion of injection equipment production facility.

    3. 1964

      Release of antituberculosis drug, Aipisit, in cooperation with Tanabe Pharma.

      Presidential commendation awarded for Aju Pharm’s efforts to eliminate tuberculosis.

    4. 1966

      Introduces for the first time in Korea, Rabonal-M, an injectable general anesthetic with a short half-life, in cooperation with Tanabe Pharma.

    5. 1967

      Construction of pharmaceutical grade raw material plant completed.

  • 1970

    1. 1975

      Commendation from the Ministry of Health & Welfare for export of raw materials.

    2. 1976

      Successfully synthesizes acetaminophen, an antipyretic analgesic; export sales reach $0.3 million.

    3. 1977

      Commendation from the Ministry of Health & Welfare for efforts to increase export of goods.

    4. 1978

      Commendation from the Ministry of Health & Welfare.

    5. 1979

      Commendation from the Ministry of Trade, Industry and Energy.

  • 1980

    1. 1983

      The current CEO, Kim Joong-kil, is named president of Aju Pharm after the passing of the founder, Kim Kwang-nam.

    2. 1984

      Aju Pharm is selected as one of the leading small and medium-sized companies by the Ministry of Science and Technology.

    3. 1986

      Terminates production of pharmaceutical grade raw materials to concentrate efforts on the manufacturing and sale of finished drugs.

  • 1990

    1. 1990

      Releases Vesseldue-F Cap, an antihyperlipidemic agent, through technical cooperation with the Italian company, Alfa Wassermann.

    2. 1992

      Construction of headquarters and KGMP plant in Pyeongtaek completed.

    3. 1995

      Research and Development center established.

    4. 1996

      Produces Profenid for Rhone-Poulenc Rorer Pharmaceuticals.

    5. 1998

      Produce Norcuron and Deca-Durabolin for Organon.

    6. 1999

      Launches Zhengchangsheng through technical cooperation with Jeil Pharmaceutical China.

      Releases Vesseldue-F, an antithrombotic agent, through technical cooperation with Alfa Wassermann.

  • 2000

    1. 2002

      Launches Uro-vaxom, a therapeutic treatment for chronic or recurrent urinary tract infections, in collaboration with the Swiss company, OM Pharma (now known as Vifor Pharma).

    2. 2004

      Produces Paoscle for Toril corporation of Japan.

    3. 2006

      Launches Bronchovaxom Cap, a COPD medication, in collaboration with OM Pharma (Vifor Pharma).

    4. 2007

      Launching of Olea, Aju Pharm’s consumer health brand.

    5. 2009

      A new plant dedicated to manufacturing cephalosporin antibiotics begins production.

  • 2010

    1. 2011

      Aju Pharm launches its Medical Devices business.

      Company name changed from Asia Pharm to Aju Pharm.

    2. 2012

      Aju Pharm is accredited by the Pharmaceuticals and Medical Device Agency of Japan as an appropriate foreign manufacturer meeting PMDA’s guidelines.

      Technology Transfer Agreement for asthma treatment research signed with Biomedical Center of Korea Research Institute of Bioscience and Biotechnology.

      Receives a presidential commendation for reaching $1.0 million in exports.

    3. 2013

      Technology Transfer Agreement and Academic-Industry Partnership Agreement signed with Dongguk University’s Medical Device Development Center.

      Establishes Regencare, a joint venture with Bestian Medical Center, a hospital specializing in burn therapy.

    4. 2014

      Construction of Medical Device plant in Bundang completed.

    5. 2016

      Construction of dedicated tablet and capsule manufacturing plant completed.